Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals; Cardior focuses on the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart
The Wall Street journal. Eastern edition, 2024-03-25Copyright 2024 Dow Jones & Company, Inc. All Rights Reserved. ;EISSN: 2574-9579
Digital Resources/Online E-Resources
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||